Sashen Ƙasashen Duniya

CT011 samfurin ƙwayoyin GPC3 CAR T ne mai zaman kansa wanda ake nema don maganin cutar kansar hanta (HCC). CT011 ya sami izinin IND daga NMPA a shekarar 2019 don maganin marasa lafiya da ke da ciwon daji mai kyau na GPC3 wanda shine gwajin IND na farko da China ta yi don maganin ƙwayoyin T na CAR akan ƙwayoyin halitta masu ƙarfi ...Kara karantawa»

Wani farfesa a jami'ar Rasha a ƙarshen shekarunsa na saba'in yana fama da cutar myeloma mai tsanani. Bayan ya yi jiyya da dama da kuma sake dawowa dashen kansa sau biyu, ya sami labarin maganin CAR-T na zamani a China, don haka ya zo China don karɓar ƙwayoyin CAR-T a wurin...Kara karantawa»

A ranar 20 ga Yuli, Hukumar Kayayyakin Lafiya ta Kasa ta China (NMPA) ta amince da amfani da sabon magani (NDA) na pCAR-19B wanda aka ƙirƙiro da kansa ta hanyar Precision Biology. Wannan samfurin shine samfurin CAR-T na farko don cutar sankarar bargo ta yara a China, wanda ake amfani da shi don magance marasa lafiya masu shekaru 3-21 ...Kara karantawa»

satricabtagene autoleucel（Satri-cel,CT041) wani samfurin ƙwayoyin T-cell ne na CAR wanda ke da ikon zama na farko a duniya. Satri-cel yana kai hari ga ƙwayoyin cuta masu ƙarfi na Claudin18.2 tare da mayar da hankali kan cutar kansar ciki/cutar haɗin gastroesophageal...Kara karantawa»

A ranar 6 ga Satumba, 2021, JW Therapeutics ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta kasar Sin ta amince da amfani da Sabon Maganin Magani (NDA) don maganin rigakafi na kwayoyin halittar CAR-T da ke hana CD19 autologous chimeric antigen receptor T (CAR-T) relmacabtagene autoleucel allura (relma-cel) ...Kara karantawa»

Equecabtagene autoleucel (eque-cel), wani maganin T-cell na maturation antigen-targeting chimeric antigen receptor (CAR) wanda aka samo daga ɗan adam, ya nuna yuwuwar maganin sake dawowa ko rashin ƙarfin myeloma mai yawa (R/RMM). A ranar 30 ga Yuni, 2023, Kayayyakin Lafiya na Ƙasa na China Sun Ba da Shawara...Kara karantawa»

A ranar 11 ga Oktoba, 2024, Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta amince da aikace-aikacen Investigational New Drug(IND) don Inaticabtagene Autoleucel (CNCT19 Allura), wani maganin CD19 mai ɗauke da autologous chimeric antigen receptor (CAR)-T cell, don magance thrombocytopenia na garkuwar jiki ...Kara karantawa»

A ranar 1 ga Maris, 2024, Hukumar Kayayyakin Lafiya ta Ƙasa ta China (NMPA) ta amince da ƙaddamar da samfurin ƙwayoyin CAR-T Zevorcabtagene AutoLeucel (Zevor-cel, CT053) don maganin manya marasa lafiya da suka sake kamuwa da cutar myeloma mai yawa waɗanda suka ci gaba bayan aƙalla layuka 3 na magani (...Kara karantawa»